Vesicular Monoamine Transport Proteins
"Vesicular Monoamine Transport Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of vesicular amine transporter proteins that catalyze the transport and storage of CATECHOLAMINES and indolamines into SECRETORY VESICLES.
| Descriptor ID |
D050493
|
| MeSH Number(s) |
D12.776.157.530.450.162.887.500.500 D12.776.157.530.562.750.500.500 D12.776.543.585.450.162.887.500.500 D12.776.543.585.562.750.500.500
|
| Concept/Terms |
Vesicular Monoamine Transport Proteins- Vesicular Monoamine Transport Proteins
- Vesicular Monoamine Transporter Proteins
- Monoamine Vesicular Transporter
- Vesicular Transporter, Monoamine
- Vesicular Monoamine Transporter
- Monoamine Transporter, Vesicular
- Monoamine Transporters, Vesicular
- Vesicular Monoamine Transporters
- Monoamine Vesicular Transport Proteins
Vesicular Monoamine Transporter 1- Vesicular Monoamine Transporter 1
- VMAT-1 Vesicular Monoamine Transporter
- VMAT 1 Vesicular Monoamine Transporter
- Chromaffin Granule Amine Transporter
|
Below are MeSH descriptors whose meaning is more general than "Vesicular Monoamine Transport Proteins".
Below are MeSH descriptors whose meaning is more specific than "Vesicular Monoamine Transport Proteins".
This graph shows the total number of publications written about "Vesicular Monoamine Transport Proteins" by people in this website by year, and whether "Vesicular Monoamine Transport Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 3 | 0 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vesicular Monoamine Transport Proteins" by people in Profiles.
-
Real-world experience with VMAT2 inhibitors in Tourette syndrome. J Neurol. 2023 Sep; 270(9):4518-4522.
-
Brain monoamine vesicular transport disease caused by homozygous SLC18A2 variants: A study in 42?affected individuals. Genet Med. 2023 01; 25(1):90-102.
-
Treatment of Tardive Dyskinesia. Neurol Clin. 2020 05; 38(2):379-396.
-
Real-World Experience With VMAT2 Inhibitors. Clin Neuropharmacol. 2019 Mar/Apr; 42(2):37-41.
-
Deutetrabenazine in the treatment of tardive dyskinesia. Neurodegener Dis Manag. 2019 04; 9(2):59-71.
-
VMAT2 Inhibitors in Neuropsychiatric Disorders. CNS Drugs. 2018 12; 32(12):1131-1144.
-
Deutetrabenazine for the treatment of Huntington's chorea. Expert Rev Neurother. 2018 08; 18(8):625-631.
-
Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. Drugs. 2018 04; 78(5):525-541.
-
Treatment options for chorea. Expert Rev Neurother. 2018 Jan; 18(1):51-63.
-
VMAT2-Mediated Neurotransmission from Midbrain Leptin Receptor Neurons in Feeding Regulation. eNeuro. 2017 May-Jun; 4(3).